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The Nuclear Receptors in Liver and Digestive Diseases research workshop was held in Rockville, Maryland,
on November 7 and 8, 2007, under the auspices of the National Institute of Diabetes and Digestive and Kidney
Diseases, National Institutes of Health. Over 130 researchers from around the world gathered to assess the
pathophysiology of nuclear receptors in the liver and gastrointestinal tract and to explore their potential use
as therapeutic targets. This review covers some of the highlights of the meeting, including important areas of
future investigation.Introduction
Knowledge of the physiology and pathophysiology of nuclear re-
ceptors (NRs) in the gut and liver is expanding rapidly, and this
NIDDK-sponsored research workshop provided the opportunity
to take stock of what we have learned and to identify priorities
for future research and clinical intervention. The meeting was
opened by a presentation by Ron Evans (Salk Institute) on the re-
cently completed spatial and temporal expression profiles for the
49 murine NRs (Bookout et al., 2006; Yang et al., 2006). Of inter-
est to this meeting, it was found that a large number of NRs are
expressed in the liver and gut, 37 and 41 respectively. The spe-
cific NRs and their association with liver and gut disorders dis-
cussed at this meeting are highlighted in Figure 1. Eight NRs
are effectively limited in expression to the liver and gut, including
the farnesoid X receptor (FXR), pregnane X receptor (PXR), con-
stitutive androstane receptor (CAR), and hepatocyte nuclear
factor 4a (HNF4a). Acting as intracellular sensors for lipophilic
molecules, these restricted NRs have essential roles in a diversity
of cellular processes including digestion, lipid and energy homeo-
stasis, and inflammation. Extensions of the NR expression profil-
ing studies are now underway to explore subpatterns of NR
expression within minority cell populations of larger tissues.
Preliminary results have revealed discrete expression patterns in
specific cell types. For example, the hepatic stellate cell (HSC),
which represents only a small percentage of the liver mass, plays
a pivotal role in hepatic fibrogenesis and vitamin A storage, as
reviewed in a presentation byScott Friedman (MountSinai School
ofMedicine). ProfilingofHSCs reveals a verydifferentNRcomple-
ment as compared to hepatocytes, the dominant hepatic cell
type. These types of observations are important not only for the
purposes of understanding these cells’ molecular and cellular
contributions to normal and disease states but also in identifying
differential targets for pharmacological manipulation. Rodent
and human tissue and cell profiles can be found in the Nuclear
Receptor Signaling Atlas (NURSA; http://www.nursa.org), an
NIH-funded data repository designed to accrue, coordinate, and
communicateexperimental data and related informationpertinent
to NRs and their functions (Margolis et al., 2005).
The meeting continued with over 25 presentations of both re-
cently published and as yet unpublished research accompaniedby lively discussion of how recent advances in the understanding
of the function of specific NRs in liver and gastrointestinal tract
could be translated into the clinical setting. Below are some
highlights.
Bile Acids, Oxysterols, Fibroblast Growth Factors,
and the Enterohepatic Axis
Although bile acids are metabolites of cholesterol that facilitate
absorption of dietary fats, it is now apparent that a subset of
bile acids act as enterohepatic hormones that coordinate several
aspects of digestion and energy homeostasis. Like their classical
steroid hormone relatives, certain bile acids are ligands for NRs,
specifically FXR, PXR, and the vitamin D receptor (VDR) (re-
viewed in Zollner et al., 2006), while related oxidized cholesterol
metabolites (oxysterols) are ligands for the liver X receptors
(LXRs). In addition, it is now apparent that NR regulation of fibro-
blast growth factors (FGFs) is important for their ability to main-
tain metabolic homoeostasis of the body.
Fasting versus Fed: NR and FGF Signaling
between Gut and Liver
In two thought-provoking presentations from the Mangelsdorf/
Kliewer laboratory (University of Texas Southwestern Medical
Center), the regulatory roles of NRs in metabolic homeostasis
during the nutritional extremes of the fasted and fed states
were covered. These studies showed that in the fasted and fed
states, peroxisome proliferator-activated receptor a (PPARa)
and FXR respectively induce the expression of a specific class
of autocrine-functioning FGFs, thereby identifying new potential
therapeutic targets. In the early fed state, oxysterols in the liver,
rapidly formed by as yet unknown mechanisms coupled to die-
tary cholesterol load, activate LXR to engage gene programs
that promote the conversions of dietary fats and carbohydrates
to triglycerides as well as promoting the elimination of excess
cholesterol through metabolism to bile acids (Kalaany and
Mangelsdorf, 2006). In the late fed state, bile acids that have
been excreted from the liver bind to FXR in the distal small intes-
tinal mucosa to promote intestinal bile acid recycling and induce
expression of FGF15 (FGF19 in humans) in intestinal entero-
cytes. FGF15 is carried in the portal circulation to the liver, where
along with bile acid-activated hepatic FXR it decreases bile acidCell Metabolism 7, March 2008 ª2008 Elsevier Inc. 195
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addition, FGF15 causes relaxation of the gallbladder, allowing it
to refill with bile (Choi et al., 2006). Bile acid-activated FXR in the
liver induces expression of genes that increase gluconeogenesis
and promote triglyceride clearance and fatty acid b-oxidation
concomitantly with a reduction of lipogenic gene transcription,
effects largely opposed to those of LXR (Kalaany and Mangels-
dorf, 2006). In the fasted state, free fatty acids are sensed by
PPARa, which in turn promotes utilization of stored fat in adipose
tissue and promotes hepatic ketogenesis to provide an alternate
energy supply to glucose for tissues such as the brain, heart, and
muscle. PPARa also induces hepatic expression of FGF21,
a ‘‘hepatokine’’ that contributes locally to ketogenesis and com-
municates between the liver and adipose tissue, promoting fat
mobilization through lipolysis in adipocytes. FGF21 also induces
an energy-conserving hibernation-like state, torpor, manifested
by a decrease in body temperature (Inagaki et al., 2007).
These presentations describing mechanisms of normal nutri-
ent and energy homeostasis were an appropriate precursor to
presentations covering the ‘‘new’’ diseases of the late twentieth
and twenty-first centuries that have their basis in excessive
nutrient intake, as covered in the following section.
NRs, NASH, and the Metabolic Syndrome
Nonalcoholic fatty liver disease (NAFLD) is the most common
liver disorder in affluent societies, representing the hepatic met-
abolic consequence of relative overnutrition and altered diet
Figure 1. Nuclear Receptors in Liver and
Gut Pathophysiology
The nuclear receptors and their associated liver
and gut diseases discussed at the NIDDK Nuclear
Receptors in Liver and Digestive Diseases re-
search workshop (Rockville, Maryland, November
2007) are highlighted in this dendrogram showing
the relationship between receptor expression,
function, physiology, and disease. (Modified from
Bookout et al., 2006.)
composition in the setting of reduced
physical activity and increased sedentary
behavior. The sometimes progressive, in-
flammatory form termed nonalcoholic
steatohepatitis (NASH) may lead to the
development of hepatic fibrosis and cir-
rhosis. Insulin resistance is almost uni-
versal in NAFLD, as is the presence of
visceral obesity (reviewed in George
and Liddle, 2008). The consensus of the
meeting was that NRs are viable thera-
peutic targets in the treatment of these
hepatic disorders. To date, human stud-
ies of NR ligands in the pharmacotherapy
of NASH have concentrated on PPARg
agonists such as rosiglitazone and piogli-
tazone. While these agents improve insu-
lin sensitivity and decrease hepatic stea-
tosis, their clinical utility is limited by
weight gain. Considerable effort is being
directed toward identifying additional NR-targeted ligands of
therapeutic value, as demonstrated by Joel Levine’s (University
of California, San Diego) study of NR expression in human
NASH liver biopsies.
PPARd is currently themost promising NR target for NASHand
themetabolic syndrome due to its powerful regulatory actions on
fat, skeletal muscle, liver, and the heart. Its activation by fatty
acids enhances fatty acid transport and oxidation, improves glu-
cose homeostasis via inhibition of hepatic glucose output, re-
duces macrophage inflammatory responses, and dramatically
increases circulating high-density lipoprotein levels (reviewed
in Barish et al., 2006). Richard Heyman (Kalypsys, Inc.) reported
that inmice fed a high-fat diet (58% fat), treatment with the selec-
tive PPARd ligand K3010 causes a reduction in visceral fat and
total body fat and a reduction in both hepatic steatosis and in-
flammation. Discussions of these findings revolved around
whether these improvements in NASH reflect direct hepatic ef-
fects or secondary effects via enhanced oxidative metabolism
in skeletal muscle and adipose tissue, which increases glucose
utilization, Glut4 expression, and processing of long-chain fatty
acids in adipose tissue. The recently reported phase I human
study of the PPARd agonist GW501516 (GlaxoSmithKline) in
moderately obesemales supports the Kalypsys data showing in-
creased fatty acid metabolism in skeletal muscle and reduction
in hepatic fat (Riserus et al., 2008). Longer-term studies of pa-
tients with insulin resistance, the broader metabolic syndrome,
and NASH are eagerly anticipated.196 Cell Metabolism 7, March 2008 ª2008 Elsevier Inc.
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Cholestatic liver diseases are characterized by impaired bile flow
and accumulation of toxic bile constituents such as bile acids in
the liver, with resultant liver injury and fibrosis. Pharmacological
therapy for chronic cholestatic disorders is limited, as reviewed
by Allan Hoffman (University of California, San Diego) and Mi-
chael Trauner (Medical University of Graz, Austria). Ursodeoxy-
cholic acid is the only cholestatic disease-modifying therapy
with evidence of efficacy, so new therapeutic approaches are
essential. Recent studies are beginning to identify NR targets
for the management of cholestasis. These studies have focused
largely on FXR, which represents an interesting dichotomy, as
both agonists and antagonists may have beneficial effects for
cholestatic liver disease. When the biliary tract is partially
blocked, activation of FXR results in enhanced bile flow through
increased hepatocyte apical bile acid transporter (ABCB11) ex-
pression, augmenting excretion of bile acids into the biliary can-
aliculus and thereby reducing bile acid accumulation in the liver.
However, in complete biliary obstruction this approach is detri-
mental, resulting in hydrostatic bile infarcts due to rupture of
the canals of Herring. Thus, in bile duct-ligatedmice, FXR knock-
outs fare better than wild-type, and upregulation of the basolat-
eral bile acid export pump Mrp4 (Abcc4) facilitates export of bile
acids out of the hepatocyte and into the circulation for renal ex-
cretion (Marschall et al., 2006; Stedman et al., 2006). These find-
ings led to the proposal of two potential therapies for cholestatic
diseases: FXR agonists may be the drug of choice for small duct
biliary diseases, while FXR antagonists may be better suited
when large duct obstruction is present.
Efforts to improve the efficacy of ursodeoxycholic acid have
led to the identification of 24-norursodeoxycholic acid, adminis-
tration of which in human subjects induces a bicarbonate-rich
choluresis (increased bile flow) and reduces the cholesterol
and phospholipid content of bile. Animal studies presented at
the meeting suggest that 24-norursodeoxycholic acid may be
superior for the treatment of cholestasis, and unpublished data
suggest that its favorable actions may in part be mediated
through activation of CAR, a NR capable of activating multiple
phase 1 and 2 detoxification enzymes in the liver as well as mod-
ulating several hepatocyte transporters (reviewed in Handschin
and Meyer, 2005).
Inflammatory Bowel Disease
In contrast to the liver, much less is known about the roles of NRs
in health and disease in the gut. Inflammatory bowel disease
(IBD) is a major clinical problem that can be refractory to even
themost potent anti-inflammatory and immunosuppressive ther-
apies. While the etiology of this disease remains unknown,
PPARg is highly expressed in the colonic epithelium, and animal
studies have shown that PPARg ligands are effective in reducing
inflammation in chemically induced models of colitis such as
dextran sodium sulfate (DSS)-treated mice. Potential mecha-
nisms of how PPARg exerts ligand-dependent transrepression
of Toll-like receptor target genes were proposed by Chris Glass
(University of California, San Diego) (Straus and Glass, 2007).
Gary Wu (University of Pennsylvania) presented exciting clinical
findings from a soon to be published study of treatment of
patients with mild to moderately active ulcerative colitis with
the PPARg agonist rosiglitazone (52 patients 4 mg twice dailyversus 53 patients placebo). A reduction in disease activity index
was observed in 44% of patients receiving rosiglitazone com-
pared to 23% of controls, and clinical improvement was usually
observed within 4 weeks of commencing therapy (Lewis et al.,
2008). Further studies are needed to determine the place of
PPARg agonists in the management of IBD, but their relative
lack of toxicity makes them an attractive treatment option
compared to existing therapies. The success of this small study
raises the possibility that these drugs may be useful prophylac-
tically to prevent disease flares.
Other NRs may also play protective roles in intestinal and
colonic mucosa. PPARd knockout mice are more susceptible
to DSS-induced colitis (Hollingshead et al., 2007), and a potent
PXR agonist ameliorates colonic inflammation in this model
(Shah et al., 2007). Taken together, these early clinical and pre-
clinical findings suggest plenty of scope for NR agonists in lumi-
nal gastrointestinal diseases, particularly those where inflamma-
tion is a predominant feature of pathogenesis, and further clinical
studies should now be a research priority given that drugs that
target these receptors are already available or soon will be.
REV-ERBa: An Orphan NR Finds a New Home?
The importance of the circadian clock in regulating metabolic
homeostasis is becoming increasingly apparent. The NRs
REV-ERBa and retinoic acid receptor-related orphan receptor
a (RORa) are integral players in circadian rhythms through their
direct regulation of the cyclic expression of brain and muscle
Arnt-like protein 1 (BMAL1), a key component of the clock.
REV-ERBa is transcribed in a cyclic manner throughout the
body and had been thought of as a constitutive repressor, as
its ligand-binding domain (LBD) lacks the domain required for
coactivator recognition. Evidence was presented at the meeting
from both the Lazar (University of Pennsylvania) and Burris (Pen-
nington Biomedical Research Center) groups (Raghuram et al.,
2007; Yin et al., 2007) that the mammalian REV-ERBa, like its
fly homolog (Reinking et al., 2005), also associates with heme.
However, in contrast to the fly, heme may bind in mammals in
a reversible manner influencing the receptor’s ability to repress
transcription of hepatic metabolic genes. In vivo, heme stabilizes
the interaction of REV-ERBa with the nuclear corepressor
(NCoR) complex, facilitating enhanced repression of target
genes. This finding, combined with the circadian cycling of intra-
cellular heme levels, led to the exciting proposal that REV-ERBa
is a heme sensor and may provide the molecular link to how cir-
cadian rhythms influence metabolic homeostasis. However, the
mechanism of how heme stabilizes the interaction of NCoR with
REV-ERBa remains elusive. In contrast to the in vivo data, addi-
tion of heme results in the dissociation of corepressor CoRNR
box peptides from the REV-ERBa ligand-binding domain in
well-characterized in vitro assays. In addition, it is unclear what
the structural consequences are of the H602F mutation in the
REV-ERBa LBD used in these studies to demonstrate that loss
of heme binding leads to loss of NCoR binding. Previous detailed
structural modeling indicated that this amino acid makes impor-
tant van der Waals interactions with other amino acids within the
LBD to stabilize the positioning of helix 11 and helix 3 (Renaud
et al., 2000). Detailed cocrystal structures of heme bound to
the REV-ERBa receptor are eagerly awaited. Collectively, these
findings raise the questions of whether REV-ERBa should nowCell Metabolism 7, March 2008 ª2008 Elsevier Inc. 197
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and whether it can be pharmacologically manipulated so as to
allow detailed mechanistic studies of the link between circadian
rhythm and hepatic metabolism.
Future Directions
Many unanswered questions concerning the distribution and
function of NRs and associated coactivator and corepressor fac-
tors in the liver and gastrointestinal tract remain. As mentioned in
the introduction of this review, we need a better understanding of
NR expression in the individual cell types that comprise tissues,
including cells that have predominantly metabolic functions,
those that have central roles in injury and inflammation, and par-
ticularly stem cell populations given their increasingly recog-
nized role in disease and tissue repair. For example, in the liver
we are finding that nonparenchymal cells have very different
NR expression patterns compared to hepatocytes. The unex-
pected expression of some ‘‘nonhepatic’’ NRs suggests entirely
new functions for these cell types and highlights the possibility of
novel therapeutics. Furthermore, again taking the liver as an ex-
ample, the humble hepatocyte exhibits zonal functional special-
ization within the hepatic lobular architecture, yet we know noth-
ing about the cause-and-effect relationships between NRs and
hepatocyte phenotypes.
The next challenge for the NR field in the area of liver and gas-
trointestinal disease is to push the translational boundary closer
to the bedside by performing more detailed studies of NR distri-
bution and function in human tissues.Much has been learned us-
ing animal and cell-based models, but effective translational re-
search could be rapidly advanced through detailed knowledge of
NR expression patterns in both normal and diseased human tis-
sues. In relation to IBD and cholestatic liver diseases, where we
are already at or near the bedside, there is plenty of scope for
medicinal chemists to develop newor improvedNR ligands to fa-
cilitate clinical studies, including FXR agonists and antagonists
for cholestasis as well as PPARg ligands designed to target
the intestinal mucosa in IBD.
Experience gained using the thiazolidinedione class of PPARg
agonists for the treatment of type 2 diabetes suggests that tar-
geting single NRs may not be the most effective strategy, just
as in vivo fatty acids activate all three PPARs. Selection of
drug targets requires a thorough understanding of NR function
across multiple tissues, including the impact of modulation of
several NRs at once. This approach is presently undergoing
late-phase clinical trials with drugs that target two or all three
members of the PPAR family.
In the context of the liver and gastrointestinal tract, a major fo-
cus of NR research is in metabolism and homeostasis. It there-
fore follows that increased use of powerful metabolomic tools
should expand our understanding of NR function, particularly
when these tools are applied to genetically modified animals
or, ideally, to the human situation in both health and disease,
a proposition that was deftly argued by Frank Gonzalez (National
Cancer Institute, NIH) in his presentation (reviewed in Idle and
Gonzalez, 2007). Some of the more obvious targets for research
within the scope of this workshop include bile acids, oxysterols,
fatty acids, and metabolic disturbances associated with obesity
and insulin resistance.198 Cell Metabolism 7, March 2008 ª2008 Elsevier Inc.Finally, it is worth considering that bile acids and possibly oxy-
sterols may have far broader functions than have been tradition-
ally ascribed to them. They are enterohepatic hormones that
coordinate digestion, energy storage, and very likely energy ex-
penditure. It has been previously recommended that bile acids
be collectively referred to as ‘‘cholanoids’’ (Hofmann et al.,
1992), a term that may better reflect their pivotal role as signaling
molecules.
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